The company

FemPulse


FemPulse GmbH was founded in 2019 as a MedTec start-up in Vienna and is developing a patented platform technology based on neurostimulation. The first product is currently being approved for the treatment of “female OAB / overactive bladder in women” and for use in EU-Europe, while further indications may be validated in clinical trials and distributed in accordance with European regulations once CE conformity has been achieved. FemPulse GmbH expects its first market approval at the end of Q4/2024.

In the USA, FemPulse Corp, which holds a minority share in FemPulse GmbH, is seeking market approval from the FDA.

FemPulse GmbH is currently supported by aws Seedfinancing (Austria Wirtschaftsservice). Further potential fields of research are in the evaluation phase. Promising indication extensions are currently undergoing clinical trials.